DadFinStart your free week
DadFin › Stocks › Healthcare › HRTX

Heron Therapeutics, Inc. (HRTX) stock score

Healthcare · Biotechnology · United States

$0.28 ▼ -8.29% today

12.0
Dad Score, out of 100
poor

Heron Therapeutics, Inc. (HRTX) is a Biotechnology company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 12.0 out of 100 on the Dad Score, a poor reading that places the business ahead of 12% of the 5,684 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #834 of 956. Its strongest axis is liquidity; its weakest are valuation and quality.

Scores from the run of Nov 15, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Weak
Quality
Below average
Growth
Average
Price action
Average
Risk
Weak
Conviction
Weak
Liquidity
Strong
Macro
Below average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)—
P/E (forward)-2.6×
Dividend yield0.00%
Return on capital-6.6%
Operating margin-5.7%
Revenue growth (YoY)+7.4%
FCF yield-16.2%
Net debt / EBITDA3.00×
Piotroski F-Score3 / 9
52-week change-71.6%
Market cap$59M
Next earningsFeb 25, 2027

What subscribers see on HRTX

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate75.0good$136.6B
REGNRegeneron Pharmaceuticals, Inc.98.6strong$98.8B
MRNAModerna, Inc.31.8weak$90.4B
ARGXargenx SE86.7strong$60.4B
ONCBeOne Medicines AG95.0strong$47.6B
RPRXRoyalty Pharma plc98.2strong$39.9B
RVMDRevolution Medicines, Inc.44.8middling$37.3B
GMABGenmab A/S63.2middling$31.7B

Prices from DadFin's live feed (refreshed about every 30 minutes in the session); scores from the weekly run of Nov 15, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.